Product Description
Mechanisms of Action: PPAR-d Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Priority Review - Cholestatic Liver Disease *
Approval Status: Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Genfit
Company Location: LOOS I0 59120
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for Elafibranor](https://pryzm-maps.s3.us-west-2.amazonaws.com/321current_maps.png)
Countries in Clinic: Argentina, Belgium, Brazil, Canada, Chile, Czech Republic, France, Germany, Italy, Poland, Portugal, Romania, South Africa, Spain, Switzerland, Turkey, United Kingdom, United States
Active Clinical Trial Count: 9
Highest Development Phases
Phase 3: Biliary Cirrhosis|Cholangitis|Liver Cirrhosis
Phase 2: Cholangitis, Sclerosing
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CLIN-60190-454 | P3 |
Recruiting |
Biliary Cirrhosis|Cholangitis |
2030-10-30 |
|
ELFIDENCE | P3 |
Recruiting |
Biliary Cirrhosis|Liver Cirrhosis|Cholangitis |
2030-10-18 |
|
2019-004941-34 | P3 |
Active, not recruiting |
Cholangitis|Biliary Cirrhosis |
2028-01-09 |
|
ELSPIRE | P3 |
Not yet recruiting |
Liver Cirrhosis|Cholangitis|Biliary Cirrhosis |
2026-06-22 |
70% |